Skip to main content

OCD Treatment with CBT

Submitted by ColumbiaOCD on January 20, 2015.

Attaining and Maintaining Wellness in OCD (IRB# 6628)

Are you between the ages of 18 - 75?

Are you taking one of the following medications for obsessive- compulsive disorder (OCD)?

Clomipramine (Anafranil)
Fluoxetine (Prozac)
Fluvoxamine (Luvox)
Sertraline (Zoloft)
Paroxetine (Paxil)
Citalopram (Celexa)
Escitalopram (Lexapro)

Are you still having bothersome symptoms?

Are you interested in receiving no-cost therapy treatment that may improve your symptoms such that you may be able to stop taking your medication?

If you answered "yes" to all four questions, you may be eligible for treatment as part of our research study “Attaining and Maintaining Wellness in OCD.” Doctors often begin OCD treatment by giving patients medications such as Anafranil, Prozac, Luvox, Zoloft, Paxil, Celexa, or Lexapro. For many patients these medications are helpful, but do not provide adequate relief of OCD symptoms. For these patients, there is a need for additional treatment options. This study investigates add-on treatments for people taking medications for their OCD, but still in need of more help.

Eligible participants initially remain on a stable dose of their OCD medication and will receive cognitive behavioral therapy consisting of Exposure and Ritual Prevention (EX/RP) twice a week for up to 12 weeks as additional treatment. Participants who become well (with only minimal to mild OCD symptoms) after the EX/RP will be randomly assigned (assigned by chance) to either continue their medication or begin to taper off their medication and have it gradually replaced with a placebo (sugar pill).

All patients will be carefully monitored throughout the study for 24 weeks. The goal of the study is to understand whether patients with OCD on Serotonin Reuptake Inhibitors (SRIs) who achieve wellness from EX/RP can safely discontinue their medication.

This study, funded by the National Institute of Mental Health, is a collaboration between Dr. Blair Simpson from Columbia University-New York State Psychiatric Institute and Dr. Edna Foa from the University of Pennsylvania.

For more information about participation, please contact Marissa Schwartz at (646)774-8062 or see our study specific website at www.ocdtreatmentstudy.com.

Locations: 

Research Clinic
1051 Riverside Drive Unit #69
10032 New York, NY
United States
Phone: 646-774-7000

Category: